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ABSTRACT
Introduction: Total ankle replacement (TAR) or ankle
arthrodesis (fusion) is the main surgical treatments for
end-stage ankle osteoarthritis (OA). The popularity of
ankle replacement is increasing while ankle fusion rates
remain static. Both treatments have efficacy but to date
all studies comparing the 2 have been observational
without randomisation, and there are no published
guidelines as to the most appropriate management.
The TAR versus arthrodesis (TARVA) trial aims to
compare the clinical and cost-effectiveness of TAR
against ankle arthrodesis in the treatment of end-stage
ankle OA in patients aged 50–85 years.
Methods and analysis: TARVA is a multicentre
randomised controlled trial that will randomise 328
patients aged 50–85 years with end-stage ankle
arthritis. The 2 arms of the study will be TAR or ankle
arthrodesis with 164 patients in each group. Up to 16
UK centres will participate. Patients will have clinical
assessments and complete questionnaires before their
operation and at 6, 12, 26 and 52 weeks after surgery.
The primary clinical outcome of the study is a validated
patient-reported outcome measure, the Manchester
Oxford foot questionnaire, captured preoperatively and
12 months after surgery. Secondary outcomes include
quality-of-life scores, complications, revision,
reoperation and a health economic analysis.
Ethics and dissemination: The protocol has been
approved by the National Research Ethics Service
Committee (London, Bloomsbury 14/LO/0807). This
manuscript is based on V.5.0 of the protocol. The trial
findings will be disseminated through peer-reviewed
publications and conference presentations.
Trial registration number: NCT02128555.
INTRODUCTION
Every year 29 000 patients with ankle osteo-
arthritis (OA) seek an opinion from ortho-
paedic foot and ankle specialists, of which
3000 will choose to undergo surgical treat-
ment on the National Health Service.1 The
main surgical treatments for end-stage ankle
OA are total ankle replacement (TAR) or
ankle arthrodesis (fusion). The popularity of
ankle replacement is increasing among
patients while ankle arthrodesis rates remain
static.2 When deciding whether to undergo
ankle replacement or arthrodesis, patients
draw on many information resources but the
majority of them rely on the advice from
their surgeon in order to make a ﬁnal deci-
sion.3 There is a paucity of quality evidence
available in order to correctly guide and
inform patient care.
To date all studies comparing ankle
replacement versus fusion have been observa-
tional and lacking randomisation and there
are no published guidelines as to the most
appropriate management. A meta-analysis of
the literature by Haddad et al4 showed that
TAR and fusion have similar intermediate
term outcomes in terms of clinical scores,
patient satisfaction and revision rate. Both
have been shown to improve quality of life at
1 year but with no difference between the
two operations.5 Another study showed a
higher risk of major revision surgery with
ankle replacement, but higher risk of
adjacent-joint fusion with ankle arthrodesis.6
This was a population-based study and
patients who received TAR and fusion may
not have been comparable.
The TAR versus arthrodesis (TARVA) trial
aims to investigate the clinical and cost-
effectiveness and complication rates of TAR
against ankle arthrodesis in the treatment of
end-stage ankle OA in patients aged 50–
85 years.
Strengths and limitations of this study
▪ TAR versus arthrodesis is the first randomised
controlled trial to compare ankle replacement
against arthrodesis.
▪ Unable to blind any postrandomisation assess-
ments due to the nature of interventions.
▪ Study is limited to the age 50–85 years.
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METHODS AND ANALYSIS
Study design
TARVA is a randomised, multicentre, non-blinded,
prospective, parallel group trial of TAR versus ankle
arthrodesis in patients with end-stage ankle OA aged
50–85 years, comparing clinical outcomes and cost-
effectiveness. An internal feasibility stage (6 months) will
be used to ensure adequate recruitment rates are
achieved and to establish surgeon willingness to random-
ise and patient willingness to be randomised. Following
the feasibility stage, an Independent Data Monitoring
Committee (IDMC) will advise whether to progress to
the substantive trial.
Inclusion criteria
Patients with end-stage ankle OA, aged 50–85 years, who
the surgeon believes to be suitable for both TAR and
arthrodesis are eligible to join the trial (having consid-
ered various patient factors including deformity, stability,
bone quality, soft tissue envelope and neurovascular
status). The patients must be able to read and under-
stand the Patient Information Sheet (PIS) and provide
written informed consent. Eligible patients (box 1) will
be randomised to a surgery type.
‘End-stage’ OA is deﬁned as a combination of severe
unrelenting symptoms sufﬁcient to make the patient con-
sider surgical intervention, radiological changes consistent
with OA and failure of at least 6 months of non-operative
measures necessitating a deﬁnitive surgical procedure.
Recruitment and consent
Patients will be recruited prospectively by the principal
investigators in outpatient clinics at participating UK
sites. If eligible for the trial, patients will be shown a
short video about the trial (available online at http://
www.anklearthritis.co.uk) and asked to read the PIS and
a generic information booklet about ankle arthritis and
its surgical treatment options. The patient can then ask
questions about the trial, and have as much time as they
need to consider the information. Written informed
consent will be obtained and details of participation in
the trial will be recorded in the clinical notes by the
research nurse.
Confidentiality
All study-related information will be stored securely at
the study site. All participant information will be stored
in locked ﬁling cabinets in areas with limited access. All
reports, data collection, process and case report forms
(CRFs) will be identiﬁed by a patient identiﬁcation (ID)
number only to maintain patient conﬁdentiality. All
records that contain names or other personal identiﬁers,
such as informed consent forms, will be stored separ-
ately from study records identiﬁed by code number. All
local databases will be secured with password-protected
access systems. Any listings that link patient ID numbers
to other identifying information will be stored in a separ-
ate, locked ﬁle in an area with limited access.
Patients’ study information will not be released outside
of the study without their written permission.
Imaging
All patients will have a preoperative standard ankle MRI
scan after providing a written informed consent. Scans
will be transferred via the Image Exchange Portal for
assessment of presence or absence of OA in the adjacent
talonavicular and subtalar joints, by a consultant radiolo-
gist at the Royal National Orthopaedic Hospital
(RNOH), Stanmore, UK. Scans will be anonymised and
stored at RNOH. The purpose of the MRI scan is to
determine the presence or absence of adjacent-joint
arthritis, as this is deemed by the investigating surgeons
to be a confounding factor for prognosis and hence
included as a stratifying variable in the randomisation.
No further MRI scans will be performed as part of the
study. But a subsequent longer term imaging outcome
study may be considered after 5–10 years subject to a
further funding application.
Timeline
The 6-month feasibility phase of the trial will start when
the ﬁrst patient is randomised. Recruitment strategies
will be reviewed during this phase to ensure that the
required sample size can be achieved in a total of
24 months of recruitment, so that the trial will have
adequate power. Further sites which treat sufﬁcient
numbers of patients with ankle OA may be opened if
deemed necessary to achieve target recruitment.
Box 1 Inclusion & exclusion criteria
Inclusion criteria
1. Patients with end-stage ankle osteoarthritis, aged 50–85 years.
2. The surgeon believes they are suitable for both total ankle
replacement and arthrodesis (having considered various patient
factors including deformity, stability, bone quality, soft tissue
envelope and neurovascular status).
3. The patients must be able to read and understand the Patient
Information Sheet and provide written informed consent.
4. Patients who are fit for surgery.
Exclusion criteria
1. Previous ipsilateral talonavicular, subtalar or calcaneocuboid
fusion or surgery planned within 1 year of index procedure.
2. More than four lower limb joints fused (including contralateral
limb, but excluding proximal interphalangeal joint (PIPJ) fusions).
3. Unable to have either an MRI or a CT scan (eg, severe claustro-
phobia or contraindication for both types of scan).
4. History of local bone or joint infection.
5. Any comorbidity, which, in the opinion of the investigator, is
severe enough to; interfere with the patient’s ability to complete
the study assessments or; presents an unacceptable risk to the
patient’s safety.
6. The patient is participating in another clinical trial that would
materially impact on their participation in this study.
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Postrecruitment withdrawals and exclusions
Patients may withdraw from the study at any time
without prejudice. Those patients who do not wish to
participate in the trial following informed consent will
be withdrawn. Data and any information about serious
adverse events obtained from this group of patients up
until the point of withdrawal will be included in the
ﬁnal analysis, in accordance with the intention-to-treat
principle, unless they explicitly request the removal of
their information from the trial database. The general
practitioners of any patients ‘lost to follow-up’ will be
contacted in an attempt to complete follow-up relating
to adverse events, complications and prescribed medica-
tions. Patients may be withdrawn from the study at the
discretion of the site principal investigator due to safety
concerns.
Randomisation
A total of 328 patients will be randomised using a mini-
misation algorithm incorporating a random element,
stratifying by surgeon and presence of OA in two adja-
cent joints (subtalar and talonavicular) as determined by
a preoperative standard ankle MRI scan. An independ-
ent online randomisation service (https://www.
sealedenvelope.com) will be used to minimise allocation
bias within the trial.
Randomisation will be carried out at each recruiting
site once the patient has been found to be ﬁt for
surgery at their preoperation assessment visit ∼2–6 weeks
before surgery. The research nurse or a delegated indi-
vidual will log on to the online randomisation service
and provide basic descriptive information (hospital,
surgeon, patient initials and date of birth) and conﬁrm-
ation of eligibility, followed by MRI scan grade:
1. Subtalar joint OA present/absent
2. Talonavicular joint OA present/absent
Once the above details have been supplied, the rando-
mised surgical allocation will be given immediately and
the patient will be notiﬁed of their allocated surgical
treatment.
Blinding
It is not possible to blind patients, surgeons, radiologists
and clinical assessors in this trial. Surgeons will know
which procedure they are performing and radiologists
will be able to identify from radiographs which proced-
ure has taken place. Patients who received ankle arth-
rodesis will know their ankle is stiff (a known
consequence of the surgery), whereas those undergoing
TAR will retain motion at the ankle.
Trial treatments
Surgeons involved in the TARVA trial are required to be
familiar with both surgical treatments. This is deﬁned as
having performed ≥10 ankle replacements and ≥10
ankle arthrodesis. If a surgeon is using a new CE-marked
ankle replacement, they must have completed a
minimum of a formal cadaveric training course and
performed a minimum of three surgeries using the
implant prior to participation in TARVA. All operation
details are recorded on a CRF, including any additional
procedures performed at the time of the primary
procedure.
Group 1: ankle replacement
The prosthesis will be inserted using the surgeon’s stand-
ard technique, which essentially involves an anterior
approach to the ankle joint avoiding the neurovascular
bundle. Once the joint is exposed it will be debrided of
osteophytes to aid entry into the joint. The talar and
tibial surfaces will be prepared according to the pros-
thesis used and its instrumentation. Most surgeons will
opt to use intraoperative ﬂuoroscopy to conﬁrm pos-
ition. Once inserted, the wound will be irrigated and
closed using the surgeon’s standard technique. Use of
ﬂuoroscopy and the surgeon’s closure technique (such
as use of drains or sutures vs clips) will be captured on a
CRF. The surgeon’s usual postoperative protocol will be
followed with respect to method of immobilisation
(plaster or walking boot) and weight-bearing status, with
details captured for each patient on the CRF.
Group 2: ankle arthrodesis
This can be carried out as an open procedure or
arthroscopically depending on the surgeons’ preference,
∼50% of operations are performed arthroscopically.1
The technique is generally the same in that the diseased
articular cartilage and subchondral bone plate are
removed to reveal bleeding cancellous bone surfaces,
and the two bone ends are opposed in the most appro-
priate position (neutral dorsiﬂexion, 5° valgus and 5°
external rotation or to match the contralateral limb)
and held with screws or plates until the joints fuse which
usually takes between 12 and 16 weeks. If performed as
an open procedure, an anterior or lateral incision is nor-
mally used. If performed arthroscopically the two
portals will be made anteromedially and anterolaterally
over the ankle joint for access. If arthroscopic access is
not favourable the operation may be converted to an
open procedure intraoperatively. The surgical technique
will be captured on the CRF. The surgeon’s usual post-
operative protocol will be followed with respect to use of
plaster or walking boot and weight-bearing status. Again
the speciﬁc details of these will be captured for each
patient on the CRF.
Follow-up schedule
Table 1 presents the trial schedule of assessments.
Patients will have clinical assessments and complete
questionnaires preoperatively, and at 2, 6, 12, 26 and
52 weeks after surgery. All patients will undergo routine
clinical review at 2 weeks when the stitches will be
removed and plaster assessed. Trial-speciﬁc outcome
measures including adverse events and postprocedural
complications will be recorded from the time of surgery
up to the 52-week visit, and costs obtained from the
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Table 1 Schedule of assessments
Visit
Screen/
introduction to
study
Follow-up
call(s) Scan
Preoperative
assessment
(baseline)
Randomisation
(inform patient)
Surgery
(week 0)
Week 2
follow-up
visit 1:
clinical
review*
Week 6
follow-up
visit 2*
Week 12
follow-up
visit 3
Week 26
follow-up
visit 4
Week 52
follow-up
visit 5
Visit timing Approximately
−12 weeks
Approximately
−6 weeks
−4 weeks −4 weeks Day 0 2 weeks 6 weeks 12 weeks 26 weeks 52 weeks
Visit window ±2 weeks ±2 weeks ±2 weeks ±2 weeks ±4 weeks ±4 weeks ±4 weeks
CRF required 1 and 2 3 5, 6, 7, 8, 9 and
20
10 11 and 20 12 and 20 13 14, 9 and 20 15,6,7,8, 9
and 20
16,6,7,8, 9
and 20
Procedure
Patient ID and screening
(inclusion/exclusion criteria)
T
Give study information T
Patient decision T
Scan booked T
Surgery slot booked R
Informed consent T (or at scan) T (if not given
at screening)
Letter to GP T
MRI (or CT) scan R/T
Full tibia X-ray R/T (any time preoperative)** T (anytime within 6 months of surgery)
Physical examination R R R R R R
EQ-5D T T T T
MOXFQ T T T
FAAM T T T
CSRI T T T T
ROM (plantar/dorsiflexion) T T
Randomisation T
Patient notified of
randomisation
T
Order kit R
Surgery R
Concomitant medication T (update log as required)
Record adverse events T (record on AE log or report on notification of SAE from consent onwards)
*In all cases, at the first post-op visit complete the Visit 1 Clinical Review. If this falls within the Visit 2 window report this as a Protocol Deviation. If Visit 2 is then missed report this as a second
Protocol Deviation.
**Only request full tibia x-ray at Scan or Pre-Op visit if not already taken as part of routine care.
AE, adverse events; CRF, case report forms; CSRI, Client Service Receipt Inventory; EQ-5D, EuroQol five dimensions; FAAM, foot and ankle ability measure; GP, general practitioner; MOXFQ,
Manchester Oxford Foot Questionnaire; R, routine procedure; trial related; ROM, range of movement; SAE, serious adverse events.
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Client Service Receipt Inventory questionnaire and
patient notes, will be recorded at baseline, 12, 26 and
52 weeks. Longer term follow-up of patients is planned
at 2, 5 and 10 years, although the analysis and publica-
tion of these results will be subject to a further funding
application by the group.
Measures of clinical effectiveness
The primary outcome is the change in the Manchester
Oxford Foot Questionnaire (MOXFQ) walking/standing
domain scores between preoperative and 52 weeks post-
operative. The MOXFQ walking/standing domain score
has been validated and is the most sensitive domain to
assess improvement in foot and ankle conditions.7 8
Secondary outcomes include the change in MOXFQ
walking/standing domain score from preoperative to
26 weeks and change in MOXFQ pain and social inter-
action domains from preoerative p to 26 and 52 weeks.
As an additional measure of physical function, the foot
and ankle ability measure (FAAM) will be captured pre-
operative and at 26 and 52 weeks. Quality of life will be
captured using the EQ-5D questionnaire preoperative
and at 12, 26 and 52 weeks.
Total range of motion of the tibia to the ﬂoor will be
captured preoperative and at 52 weeks. This will formally
assess plantarﬂexion and dorsiﬂexion using a goniom-
eter and a standardised technique. This range includes
motion at the hindfoot, midfoot and forefoot joints, and
is relevant as it reﬂects the functional range of motion
the patient shall experience irrespective of the isolated
motion (or absence of) at the tibiotalar (ankle) joint.
All adverse events, serious adverse events and complica-
tions reported from the date of surgery until the ﬁnal
follow-up visit at 52 weeks (±4 weeks) will be recorded.
Patients who require further interventions during the
study period will be eligible for standard care as if those
happened outside of the study. Details of any additional
interventions or treatments will be recorded as a
(serious) adverse event ((S)AE) and reported under the
safety outcome.
Power and sample size
The planned total sample size is 328 patients; 164
patients enrolled to each surgical treatment group. This
sample size will give 90% power using the 5% signiﬁ-
cance level to detect a difference of 12 in the post-
operative change in the MOXFQ walking/standing
domain score between the two surgical treatment groups
assuming a SD of 27,9 a surgeon intraclass coefﬁcient of
0.03 (the extent to which the difference between the 2
procedures varies between surgeons), average of 14
patients per surgeon, and a loss to follow-up of 10%.
Statistical analysis
The main analysis will be conducted following the modi-
ﬁed intention-to-treat principle. We will analyse the data
from all patients who undergo surgery, in accordance
with their randomised surgical procedure. Only those
patients who do not undergo surgery of any kind will be
excluded from the analysis. We will also conduct a sensi-
tivity analysis for the primary outcome measure where
we will analyse the data from all participants who
undergo surgery according to the surgical procedure
received, if cross-over prior to surgery does occur. Any
cross-overs or other treatment deviations, as well as the
number of patients who did not undergo surgery of any
kind will be speciﬁed along with reasons.
For the primary outcome, analysis of the change in
MOXFQ walking/standing domain score, we will use a
mixed linear regression model that will include a ﬁxed
effect for treatment, baseline MOXFQ and presence of
OA in two adjacent joints as determined by a preopera-
tive MRI scan, along with a random surgeon effect and
random surgeon by treatment interaction to take
account of clustering by surgeon. We will include all
patients with any follow-up data in these models. Missing
covariate data are not anticipated since covariates must
be recorded to allocate treatment. Missing outcome data
will be assumed to be missing at random, conditional on
any variable included in the analysis model (MAR), and
so independent of the values of the unobserved data
themselves. Any missing outcome data will therefore be
handled naturally by the linear mixed model, which is
robust to the MAR assumption. Continuous secondary
outcome measures will be analysed similarly. Serious
adverse events, revision surgery and complication rates
in the two groups will be compared using relative risks
calculated from a binomial regression model.
An exploratory subgroup analysis will be performed to
investigate whether there is any interaction between the
effect of treatment and the presence of OA in the two
adjacent joints as determined from the preoperative MRI
scan. While we may predict that patient reported
outcome measure (PROM) scores in patients who had
TAR will be better than in patients who had arthrodesis
when there is OA in adjacent joints, we accept that this
question may only be answered once the 5-year and
10-year follow-up data are available. Based on the ﬁnd-
ings of SooHoo et al,6 it is further hypothesised that
patients undergoing arthrodesis may experience more
adjacent-joint arthritis than those undergoing TAR.
Long-term continuous outcomes will similarly be ana-
lysed with linear mixed regression models. Treatment
and time will be modelled along with the interaction
between them. The models will include random surgeon
effects and ﬁxed effects for the presence of OA in adja-
cent joints at baseline as determined by the preoperative
MRI scan. Long-term binary outcomes (revision surgery,
reoperation other than revision and adjacent-joint OA)
will be modelled using mixed logit models.
A statistical analysis plan will be agreed before the ﬁrst
substantive statistical analysis and approved by the
Independent Trial Steering Committee (TSC). Any con-
ﬁdential interim analyses will be performed at the
request of the IDMC. All statistical tests will use a two-
sided p=0.05, unless otherwise speciﬁed. There will be
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no formal adjustment of p values for any interim ana-
lyses performed. All CIs presented will be 95% and two
sided. All statistical analysis will be performed using
Stata (StataCorp, College Station, Texas, USA).
Health economics analysis
We will undertake a detailed analysis of the cost and
cost-effectiveness of TAR versus ankle arthrodesis in
patients with end-stage ankle OA. Our analysis will
conform to recommended economic evaluation
methods such as those from the National Institute for
Health and Care Excellence (NICE).10 For the primary
economic analysis costs will be assessed from the per-
spective of the NHS and personal social services while
secondary analysis will consider additional costs borne
by the patient as well as societal costs. We will estimate
cost and cost-utility for the ‘within-trial’ period, based on
the clinical and health-related quality-of-life results at
baseline and follow-up. We will also extrapolate beyond
the trial period to estimate cost-effectiveness over the
expected lifetime of the patients.
Costs and utilities
Health service costs associated with treatment will
include the cost of the surgery by type (including cost of
implants), perioperative complications, tests undertaken,
boot and plaster changes, revision and reoperation
surgery by type and overall hospital length of stay. We
will ask patients to tell us about their outpatient atten-
dances, hospital readmissions, primary care contacts,
physiotherapy sessions, accident and emergency atten-
dances and prescribed medications. For the broader
societal analysis we will also ask the patients to tell us
about the costs they would incur as part of their OA
treatment, including time and travel costs incurred in
the receipt of care, out-of-pocket expenditures and time
off work. The volume of resource for each cost compo-
nent will be measured directly in the trial from both
patient records and through patient self-report forms.
Unit costs will be taken from standard published
sources.
Patient-speciﬁc utility proﬁles will be constructed
assuming a linear change in utility values measured at
each time point. Utility estimates will be calculated
according to the area under the curve approach, adjust-
ing for baseline differences in patients in the trial arms
if necessary.
Within-trial and model-based analysis
The cost-effectiveness measures in the 1-year model will
be the incremental cost per unit increase in MOXFQ
and the incremental cost per quality-adjusted life year
(QALY) gained. QALYs will be calculated based on the
responses to the EQ-5D collected at baseline and speci-
ﬁed follow-up points.
In the lifetime model, cost-effectiveness will be calcu-
lated in terms of the incremental cost per QALY gained.
A review of previous cost-effectiveness and cost-utility
analyses will be conducted to identify any existing mod-
elling work that may be drawn for developing the model
structure and informing model parameters. In the UK,
there are no previous studies of the cost-effectiveness of
ankle arthrodesis versus ankle replacement, but a
number of health technology assessment (HTA)-funded
studies have been undertaken on the cost-effectiveness
of hip replacement surgery, which may yield relevant
economic model structures. The speciﬁc details of the
data required to populate the model will be determined
following the development of the model structure. We
will undertake deterministic (one way, two way and
multiway) and probabilistic sensitivity analysis, the latter
assuming appropriate distributions and parameter
values that will also be used to construct cost-
effectiveness acceptability curves.
Analysis methods
Both the within-trial and model-based analyses will be
undertaken within a Bayesian framework. Methods for
conducting economic evaluation using clinical trial data
will be applied following O’Hagan and Stevens11 and
O’Hagan, Stevens and Montmartin.12 Monte Carlo simu-
lation methods will be used to construct a cost-
effectiveness acceptability curve, based on the expected
net beneﬁt statistic, to estimate the probability that the
intervention is cost-effective for a range of values of soci-
etal willingness to pay per QALY. We will also subject the
results to extensive deterministic (one-way, two-way and
multiway) sensitivity analysis. Missing EQ-5D and
resource use data will be addressed using appropriate
statistical methods in consultation with the trial
statistician.
Dissemination
The ﬁndings of this study will be disseminated through
peer-reviewed publications and conference presentations.
Access to data
The Comprehensive Clinical Trials Unit (CCTU) will
oversee data sharing, with input from the Trial
Management Group.
Data will be stored on a password-protected MACRO
database. Site staff will have direct access to their own
site’s data. No patient identifying information is
recorded on the database.
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